Possible mechanisms for the effects of botulinum toxin on pain

Clinical Journal of Pain

Volumn 18, Issue 6 SUPPL., 2002, Pages

  Arezzo, Joseph C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; CALCIUM CHANNEL; GABAPENTIN; GLUTAMIC ACID; SUBSTANCE P;

AFFERENT NERVE GROUP 1; ANALGESIC ACTIVITY; AUTONOMIC NERVOUS SYSTEM; CHOLINERGIC NERVE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GAMMA MOTONEURON; HUMAN; HYPERALGESIA; MUSCLE CONTRACTION; MYALGIA; NERVE CELL PLASTICITY; NOCICEPTION; NONHUMAN; PAIN; PAIN ASSESSMENT; PAIN RECEPTOR; PRIORITY JOURNAL; REVIEW; SOMATOSENSORY STIMULATION; STIMULUS RESPONSE;

ACETYLCHOLINE; AUTONOMIC NERVOUS SYSTEM; BOTULINUM TOXINS; HUMANS; MUSCLE SPINDLES; MUSCLE, SKELETAL; NEURONAL PLASTICITY; NEURONS; PAIN;

EID: 0036840904     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002508-200211001-00003     Document Type: Review

References (78)

1. Swaminathan S, Eswaramoorthy S. Crystal structure of clostridium botulinum neurotoxin serotype B. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:29-39.
2. Hanson MA, Stevens RC. Structural view of botulinum neurotoxin in numerous functional states. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:11-27.
3. Rossetto O, Caccin P, Rigoni M, et al. The metalloprotease activity of tetanus and botulinum neurotoxins. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams and Wilkins, 2002:3-10.
4. Singh BR. Molecular basis of the unique endopeptidase activity of botulinum neurotoxin. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:75-88.
5. Sutton JM, Spaven L, Silman NJ. The receptor binding domains of clostridial neurotoxins. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:41-8.
6. O'Brien CF. Clinical applications of botulinum toxin: Implications for pain management. Pain Digest 1998;8:342-5.
7. Göbel H, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndrome. Pain 2001;91:195-9.
8. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin Invest Drugs 2001;10:1531-44.
9. Brin MF, Binder W, Blitzer A. Botulinum toxin type A BOTOX® for pain and headache. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:233-50.
10. Royal MA. The use of botulinum toxins in the management of myofascial pain and other conditions associated with painful muscle spasm. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:309-21.
11. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-54.
12. Wissel J, Mǔller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Sympt Manag 2000;20:44-9.
13. Jankowitz J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dystonia, other focal distonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-9.
14. Priori A, Berardeli A, Mercuri B, et al. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between muscles. Brain 1995;118:801-7.
15. Lew MF, Adornato BT, Duane DD. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
16. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain 1993;64:241-89.
17. Marchettini P. Muscle pain: Animal and human experimental and clinical studies. Muscle Nerve 1993;16:1033-9.
18. Mense S. Nociceptors in skeletal muscle and their reaction to pathological tissue changes. In: Belmonte C, Cervero F, eds. Neurobiology of Nociceptors. Oxford, New York, Tokyo: Oxford University Press, 1996:184-201.
19. Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: Evidence from animal and human studies. Clin J Pain 2001;17:2-10.
20. Babenko V, Graven-Nielsen T, Svensson P, et al. Experimental human muscle pain and muscular hyperalgesia induced by combinations of serotonin and bradykinin. Pain 1999;82:1-8.
21. Babenko V, Svensson P, Graven-Nielsen T, et al. Duration and distribution of experimental muscle hyperalgesia in humans following combined infusions of serotonin and bradykinin. Brain Res 200;853:275-81.
22. Rotto DM, Kaufman MP. Effect of metabolic products of muscular contraction on discharge of group III and IV afferents. J Appl Physiol 1988;64:2306-13.
23. Dowd E, McQueen DS, Chessell IP, et al. P2X receptor-mediated excitation of nociceptive afferents in the normal and arthritic rat knee joint. Br J Pharmacol 1998;125:341-6.
24. Hamilton SG, McMahon SB. ATP as a peripheral mediator of pain. J Auton Nerv Syst 2000;81:187-94.
25. Reinert A, Kaske A, Mense S. Inflammation-induced increase in the density of neuropeptide-immunoreactive nerve endings in rat skeletal muscle. Exp Brain Res 1998;121:174-80.
26. Gerwin RD. Myofascial pain syndromes in the upper extremity. J Hand Ther 1997;10:130-6.
27. Schomburg ED, Steffens H, Klaus-Dieter K. Contribution of group III and IV muscle afferents to multisensorial spinal motor control in cats. Neurosci Res 1999;33:195-206.
28. Simons DG, Mense S. Understanding and measurement of muscle tone as related to clinical muscle pain. Pain 1998;75:1-17.
29. Mense S. Pathophysiologic basis of muscle pain syndromes. Phys Med Rehab Clin North Am 1997;8:23-53.
30. Matre DA, Sinkjaer T, Svensson P, Arendt-Nielsen L. Experimental muscle pain increases the human stretch reflex. Pain 1998;75:331-9.
31. Filippi GM, Errico P, Santarelli R, et al, Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400-4.
32. Rosales RL, Arimura K, Takenga S, et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-96.
33. Kandel ER, Schwartz JH, Jessell TM. Principles of Neural Science. 4th Ed. New York, McGraw-Hill, 2001.
34. Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997;152:132-5.
35. Guyer BM. Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999;3:427-31.
36. Hallett M. How does botulinum toxin work? Am Neurol Assoc 2000;48:7-8.
37. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248:1/3-1/10.
38. Travell J, Rinzter S, Herman M. Pain and disability of the shoulder and arm. JAMA 942;120:417-22.
39. Johansson H, Sojka P. Pathophysiological mechanisms involved in genesis and spread of muscular tension in occupational muscle pain and in chronic musculoskeletal pain syndromes: A hypothesis. Med Hypoth 1991;35:196-203.
40. Knutson GA. The role of the γ-motor system in increasing muscle tone and muscle pain syndromes: A review of the Johansson/Sojka hypothesis. J Manipul Physiol Ther 2000;23:564-71.
41. Wadell I, Johansson H, Sjölander P, et al. Fusimotor influencing secondary muscle spindle afferents from flexor and extensor muscle in the hind limb of the cat. J Physiol 1991;85:223-34.
42. Donaldson CCS, Nelson DV, Schultz R. Disinhibition in the gamma motorneuron circuitry: A neglected mechanism for understanding myofascial pain syndrome? Appl Psychophysiol Biofeedback 1988;23:43-57.
43. Murphy PR, Martin HA. Cutaneous reflex control of fusimotor neurons. In: Taylor A, Gladden M, Durbaba R, eds. Alpha and Gamma Motor Systems. New York: Plenum Press, 1995:145-9.
44. Sjölander P, Johansson H. Influences on the γ-muscle spindle system from joint mechanoreceptors. In: Taylor A, Gladden M, Durbaba R, eds. Alpha and Gamma Motor Systems. New York: Plenum Press. 1995:137-44.
45. Jenzer G, Mumenthaler M, Ludin HP, et al. Autonomic dysfunction in botulism B: A clinical report. Neurology 1975;25:150-3.
46. Pal PK, Calne DB, Calne S, et al. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7.
47. Naumann M, Flachenecker P, BrOcker E-B, et al. Botulinum toxin for palmar hyperhidrosis. Lancet 1997;349:252.
48. Claus D, Druschky A, Erbguth F. Botulinum toxin: Influence on respiratory heart rate variation. Mov Disord 1995;10:574-9.
49. Kellogg DL Jr, Pergola PE, Piest KL, et al. Cutaneous active vasodilatation in humans is mediated by cholinergic nerve cotransmission. Circ Res 1995;77:1222-8.
50. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol 2001;281:H2124-32.
51. Pedersen-Bjergaard U, Nielsen LB, Jensen K, et al. Calcitonin gene-related peptide, neurokinin A and substance P: Effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 1991;12:333-7.
52. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995;15:277-80.
53. Daeman M, Kurversh H, Bullens P, et al. Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model). Acta Orthop Belg 1998;64:441-7.
54. Dray A. Tasting the inflammatory soup: The role of peripheral neurons. Pain Rev 1994;1:153-71.
55. Dray A. Neurogenic mechanisms and neuropeptides in chronic pain. In: Carli G, Zimmermann M, eds. Progress in Brain Research. Vol. 110. New York: Elsevier Science, 1996:85-94.
56. Mense S, Hoheisel U, Reinert A. The possible role of substance P in eliciting and modulating deep somatic pain. In: Carli G, Zimmermann M, eds, Progress in Brain Research. Vol. 110. New York: Elsevier Science, 1996:125-135.
57. Mannion RJ, Woolf C. Pain mechanisms and management: A central perspective. Clin J Pain 2000;16:S144-56.
58. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-9.
59. Lu WY, Xiong ZG, Lei S, et al. G-protein-coupled receptors act via protein kinase C and src to regulate NMDA receptors. Nature Neurosci 1999;4:331-8.
60. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992;356:521-3.
61. Woolf CJ, Costigan M. Transcriptional and posttranscriptional plasticity and the generation of inflammatory pain. Proc Nad Acad Sci USA 1999;96:7723-30.
62. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1 betamediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
63. 125I-labeled botulinum toxin A into the spinal cord and on the action of unlabeled botulinum toxin A in the spinal cord and in the nictitating membrane. Acad Sci Arts Bosnia Herzegovina 1976;29:91-8.
64. Wiegand H, Welhoner HH. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 1977;298:235-8.
65. Aoki R. The development of BOTOX - Its history and pharmacology. Pain Digest 1998;8:337-41.
66. Berardelli A, Gilo F, Currà A. Effects of botulinum toxin type A on central nervous system function. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Bontulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002:171-7.
67. Byrnes ML, Thickbroom GW, Wilson SA, et al. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 1998;121:977-88.
68. Schnitzler A, Ploner M. Neurophysiology and functional neuroanatomy of pain perception. J Clin Neurophysiol 200;17:592-603.
69. Bigalke H, Heller L, Bizzini B, et al. Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studies with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1981;316:244-51.
70. Ashton AC, Dolly JO. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J Neurochem 1988;50:1808-16.
71. McMahon HT, Foran P, Dolly JO, et al. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, γ-aminobutyric acid, asparate, and met-enkephalin release from synaptosomes. J Biol Chem 1992;267:21338-43.
72. Purkiss J, Welch M, Soward S, et al. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms. Biochem Pharmacol 200;59:1403-6.
73. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthahnol 2000;44:106-9.
74. Cui ML, Khanijou S, Rubino J, et al. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Soc Neurosci Abst 2000;26:656 (abstract).
75. Cui M, Li Z, You S, et al. Mechanisms of the antinociceptive effect of subcutaneous Botox®: Inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002;365:33.
76. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botalinum neurotoxins. Toxicon 2000;38:245-58.
77. Black JD, Dolloy JO. Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems. Neuroscience 1987;23:767-79.
78. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001;21:1868-75.